Angiostatin endostatin gene therapy - Oxford BioMedica

Drug Profile

Angiostatin endostatin gene therapy - Oxford BioMedica

Alternative Names: Angiostatin lentivector gene therapy; EIAV.angiostatin - Oxford bioMedica; EIAV.endostatin - Oxford BioMedica; Endostatin lentivector gene therapy; OXB-201; RetinoStat

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 10 Oct 2016 Efficacy, adverse events and pharmacokinetics data from a phase I trial in wet Age related macular degeneration released by Oxford Biomedcia
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
  • 29 Apr 2014 Sanofi has advised that it will not be taking up the option to continue development of Angiostatin endostatin gene therapy beyond phase I trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top